GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Janux Therapeutics Inc (NAS:JANX) » Definitions » Market Cap

JANX (Janux Therapeutics) Market Cap : $3,605.92 Mil (As of Dec. 12, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Janux Therapeutics Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Janux Therapeutics's share price for the quarter that ended in Sep. 2024 was $45.43. Janux Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Sep. 2024 was 52.34 Mil. Therefore, Janux Therapeutics's market cap for the quarter that ended in Sep. 2024 was $2,377.68 Mil.

Janux Therapeutics's quarterly market cap increased from Mar. 2024 ($1,951.80 Mil) to Jun. 2024 ($2,185.07 Mil) and increased from Jun. 2024 ($2,185.07 Mil) to Sep. 2024 ($2,377.68 Mil).

Janux Therapeutics's annual market cap declined from Dec. 2021 ($813.73 Mil) to Dec. 2022 ($548.09 Mil) and declined from Dec. 2022 ($548.09 Mil) to Dec. 2023 ($496.29 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Janux Therapeutics's Enterprise Value for Today is $3,085.65 Mil.


Janux Therapeutics Market Cap Historical Data

The historical data trend for Janux Therapeutics's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Janux Therapeutics Market Cap Chart

Janux Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
- - 813.73 548.09 496.29

Janux Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 465.21 496.29 1,951.80 2,185.07 2,377.68

Competitive Comparison of Janux Therapeutics's Market Cap

For the Biotechnology subindustry, Janux Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Janux Therapeutics's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Janux Therapeutics's Market Cap distribution charts can be found below:

* The bar in red indicates where Janux Therapeutics's Market Cap falls into.



Janux Therapeutics Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Janux Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$10.73*46.2524
=$496.29

Janux Therapeutics's Market Cap for the quarter that ended in Sep. 2024 is calculated as

Market Cap (Q: Sep. 2024 )=Share Price (Q: Sep. 2024 )*Shares Outstanding (EOP) (Q: Sep. 2024 )
=$45.43*52.3372
=$2,377.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Janux Therapeutics  (NAS:JANX) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Janux Therapeutics Market Cap Related Terms

Thank you for viewing the detailed overview of Janux Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Janux Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
10955 Vista Sorrento Parkway, Suite 200, San Diego, CA, USA, 92130
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.
Executives
David Alan Campbell director, officer: Chief Executive Officer C/O JANUX THERAPEUTICS, INC., 11099 N. TORREY PINES ROAD, SUITE 290, LA JOLLA CA 92037
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Avalon Ventures Xi, L.p. 10 percent owner 1134 KLINE STREET, LA JOLLA CA 92037
Andrew Hollman Meyer officer: Chief Business Officer C/O JANUX THERAPEUTICS, INC., 11099 N. TORREY PINES ROAD, SUITE 290, LA JOLLA CA 92037
Jay Lichter director, 10 percent owner C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340, LEAWOOD KS 66211
Tighe Reardon 10 percent owner, officer: Acting Chief Financial Officer C/O SYNTHORX, INC., 11099 NORTH TORREY PINES ROAD, SUITE 190, LA JOLLA CA 92037
Ra Capital Nexus Fund Ii, L.p. director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Charles M. Winter officer: Chief Technical Officer C/O JANUX THERAPEUTICS, INC., 10955 VISTA SORRENTO PARKWAY, SUITE 200, SAN DIEGO CA 92130
Winston Kung director C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
Byron Robinson officer: Chief Strategy Officer C/O JANUX THERAPEUTICS, INC., 11099 N. TORREY PINES ROAD, SUITE 290, LA JOLLA CA 92037
Orbimed Advisors Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Peter A. Thompson director C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Orbimed Capital Gp Viii Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629
Orbimed Genesis Gp Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Vii Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022